MedTrace Logo

Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice

NCT02202837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 157

Last updated 2018-12-03

Study results available
· View outcomes & findings →

Summary

Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with Etanercept

Conditions

Interventions

DRUG

etanercept

etanercept 1 x 50 mg/week or 2 x 25mg/week

DRUG

etanercept

etanercept 1 x 50 mg/week or 2 x 25mg/week

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-12
Primary Completion
2017-04-24
Completion
2017-04-24

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202837 on ClinicalTrials.gov